Median age of 3L patients was 58 years (range 20–87 years); 110 (58%) were male, 45 (24%) had secondary or therapy-related AML, and 20 (11%) had FLT3-ITD mutation (Table 1). This evidence concerns the gene FLT3 and acute myeloid leukemia.